Pacritinib - CAS# 937272-79-2 adib) BxPC-3 primary tumor growth in

BxPC-3 primary tumor growth in the MIA-PaCa-2 early-stage model and early-stage model of BxPC-3

InChi: InChI=1S/C16H23N5O

The combination of inhibitory activities on independent kinase and bromodomain oncogenic pathways exemplifies a new strategy for rational single-agent polypharmacological targeting

CAS Number: 1010085-13-8

Pacritinib - CAS# 937272-79-2 adib) BxPC-3 primary tumor growth inPacritinib, also known as SB1518, is a n orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK STAT signaling pathway, and so caspase dependent apoptosis. JAK2 is the most common mutated gene in bcr abl negative myeloproliferative disorders; the JAK2V617F gain of